[go: up one dir, main page]

JP2014533929A - ５ｔ４およびｃｄ３に対する二重特異的結合性分子 - Google Patents

５ｔ４およびｃｄ３に対する二重特異的結合性分子 Download PDF

Info

Publication number
JP2014533929A
JP2014533929A JP2014531248A JP2014531248A JP2014533929A JP 2014533929 A JP2014533929 A JP 2014533929A JP 2014531248 A JP2014531248 A JP 2014531248A JP 2014531248 A JP2014531248 A JP 2014531248A JP 2014533929 A JP2014533929 A JP 2014533929A
Authority
JP
Japan
Prior art keywords
seq
cdr
human
antibody
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014531248A
Other languages
English (en)
Japanese (ja)
Inventor
クファー，ペーター
キシェル，ローマン
ラウム，トビアス
ラウ，ドリス
ルッタービューゼ，ラルフ
ホフマン，パトリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Micromet GmbH
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet GmbH, Amgen Research Munich GmbH filed Critical Micromet GmbH
Publication of JP2014533929A publication Critical patent/JP2014533929A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2014531248A 2011-09-23 2012-09-21 ５ｔ４およびｃｄ３に対する二重特異的結合性分子 Pending JP2014533929A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161538716P 2011-09-23 2011-09-23
US61/538,716 2011-09-23
PCT/EP2012/068673 WO2013041687A1 (en) 2011-09-23 2012-09-21 Bispecific binding molecules for 5t4 and cd3

Publications (1)

Publication Number Publication Date
JP2014533929A true JP2014533929A (ja) 2014-12-18

Family

ID=47088803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014531248A Pending JP2014533929A (ja) 2011-09-23 2012-09-21 ５ｔ４およびｃｄ３に対する二重特異的結合性分子

Country Status (6)

Country Link
EP (1) EP2758438A1 (de)
JP (1) JP2014533929A (de)
AU (1) AU2012311492A1 (de)
CA (1) CA2846432A1 (de)
MX (1) MX2014003313A (de)
WO (1) WO2013041687A1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170094319A (ko) * 2014-12-19 2017-08-17 바이오테크놀 리미티드 5t4 및 cd3에 대한 3개 결합 도메인을 포함하는 융합 단백질
JP2019508023A (ja) * 2015-12-24 2019-03-28 エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド Ｔｐｂｇ抗体およびその調製方法、その共役体並び用途
JP2020530770A (ja) * 2017-07-20 2020-10-29 アプティーボ リサーチ アンド デベロップメント エルエルシー 癌胎児性抗原結合タンパク質、関連する化合物および方法
JP2021517457A (ja) * 2018-03-12 2021-07-26 ゲンマブ エー／エス 抗体

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367851B (es) 2013-10-11 2019-09-09 Mersana Therapeutics Inc Conjugados de proteína-polímero-fármaco.
IL245009B (en) 2013-10-11 2022-08-01 Asana Biosciences Llc Protein-polymer-drug conjugates
MA40069A (fr) 2014-05-29 2021-04-14 Macrogenics Inc Molécules de liaison trispécifiques et leurs procédés d'utilisation
EP3164417A1 (de) 2014-07-01 2017-05-10 Pfizer Inc. Bispezifische heterodimere diabodies und verwendungen davon
WO2016022939A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
CA3006462C (en) 2015-12-14 2023-10-31 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
ES2910365T3 (es) * 2016-04-22 2022-05-12 Alligator Bioscience Ab Nuevos polipéptidos biespecíficos contra CD137
CN109310762A (zh) 2016-06-07 2019-02-05 宏观基因有限公司 联合疗法
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018156740A1 (en) 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
US11866507B2 (en) 2017-04-11 2024-01-09 Inhibrx, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
EP3717021A1 (de) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepin-antikörper-konjugate
CN111465618A (zh) 2017-12-12 2020-07-28 宏观基因有限公司 双特异性cd16-结合分子及其在疾病治疗中的用途
EP3727463A1 (de) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepin-antikörper-konjugate
MX2020008489A (es) 2018-02-15 2020-09-25 Macrogenics Inc Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades.
JP2021520812A (ja) 2018-04-11 2021-08-26 インヒブルクス インコーポレイテッド 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用
US12195533B2 (en) 2018-07-24 2025-01-14 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
JP2022504802A (ja) * 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
JP2022513400A (ja) 2018-10-29 2022-02-07 メルサナ セラピューティクス インコーポレイテッド ペプチド含有リンカーを有するシステイン操作抗体－薬物コンジュゲート
WO2021048423A1 (en) 2019-09-12 2021-03-18 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
JP2025512377A (ja) 2022-04-11 2025-04-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ユニバーサルな腫瘍細胞殺傷のための組成物及び方法
WO2024173830A2 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (de) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformationsvektoren für Hefe Yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP1978033A3 (de) 1995-04-27 2008-12-24 Amgen Fremont Inc. Aus immunisiertem Xenomid abgeleitete menschliche Antikörper
EP0823941A4 (de) 1995-04-28 2001-09-19 Abgenix Inc Menschliche antikörper aus xenomäusen
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
EP0983303B1 (de) 1997-05-21 2006-03-08 Biovation Limited Verfahren zur herstellung von nicht-immunogenen proteinen
IL132596A0 (en) 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector
AU761587B2 (en) 1998-04-21 2003-06-05 Amgen Research (Munich) Gmbh CD19xCD3 specific polypeptides and uses thereof
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
WO2002038612A2 (en) 2000-11-13 2002-05-16 Oxford Biomedica (Uk) Limited Canine and feline tumour-associated antigen 5t4
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GT200500255A (es) * 2004-09-10 2006-04-10 Anticuerpos anti-5ta humanizados y conjugados anticuerpo anti-5ta/calicheamicina
JP4926168B2 (ja) * 2005-05-13 2012-05-09 オックスフォード バイオメディカ（ユーケー）リミテッド ペプチド
DK2368914T3 (en) 2006-03-10 2019-03-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
EP2225275A4 (de) * 2007-11-28 2013-04-03 Medimmune Llc Proteinformulierung

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170094319A (ko) * 2014-12-19 2017-08-17 바이오테크놀 리미티드 5t4 및 cd3에 대한 3개 결합 도메인을 포함하는 융합 단백질
JP2018500025A (ja) * 2014-12-19 2018-01-11 バイオテクノル リミテッドＢｉｏｔｅｃｎｏｌ Ｌｉｍｉｔｅｄ ５ｔ４及びｃｄ３に対する３つの結合ドメインを含む融合タンパク質
KR102495820B1 (ko) 2014-12-19 2023-02-06 치오메 바이오사이언스 가부시키가이샤 5t4 및 cd3에 대한 3개 결합 도메인을 포함하는 융합 단백질
JP2019508023A (ja) * 2015-12-24 2019-03-28 エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド Ｔｐｂｇ抗体およびその調製方法、その共役体並び用途
JP2020530770A (ja) * 2017-07-20 2020-10-29 アプティーボ リサーチ アンド デベロップメント エルエルシー 癌胎児性抗原結合タンパク質、関連する化合物および方法
JP7369113B2 (ja) 2017-07-20 2023-10-25 アプティーボ リサーチ アンド デベロップメント エルエルシー 癌胎児性抗原結合タンパク質、関連する化合物および方法
JP2021517457A (ja) * 2018-03-12 2021-07-26 ゲンマブ エー／エス 抗体
JP2022184914A (ja) * 2018-03-12 2022-12-13 ジェンマブ エー／エス 抗体
JP7209008B2 (ja) 2018-03-12 2023-01-19 ジェンマブ エー／エス 抗体
JP7447208B2 (ja) 2018-03-12 2024-03-11 ジェンマブ エー／エス 抗体
JP2024054405A (ja) * 2018-03-12 2024-04-16 ジェンマブ エー／エス 抗体

Also Published As

Publication number Publication date
EP2758438A1 (de) 2014-07-30
AU2012311492A1 (en) 2014-03-06
CA2846432A1 (en) 2013-03-28
MX2014003313A (es) 2014-07-09
WO2013041687A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
US12281176B2 (en) Binding molecules for BCMA and CD3
JP2014533929A (ja) ５ｔ４およびｃｄ３に対する二重特異的結合性分子
JP6407726B2 (ja) 長寿命ポリペプチド結合分子
CN111484556A (zh) Bcma和cd3的结合分子
WO2016135239A1 (en) Fusion protein comprising three binding domains to her2
HK40021467A (en) Binding molecules for bcma and cd3
HK40022686A (en) Binding molecules for bcma and cd3
HK1198040A (en) Binding molecules for bcma and cd3
HK1198040B (en) Binding molecules for bcma and cd3